Showing 1 – 20 of 5229
Relevance | Newest | Oldest |
  • JAMA May 10, 2016

    Figure 2: Study Flow of Trial Comparing Same vs Different Order for Presenting Batches of Mammograms to Breast Screening Readers

    aEach screening included 4 mammograms (mediolateral oblique and craniocaudal views of both breasts).bFor each screening, there may be multiple reasons why they did not receive the allocated intervention.cNational Breast Screening Service (NBSS) records are the electronic health records of women screened.
  • Effect of Using the Same vs Different Order for Second Readings of Screening Mammograms on Rates of Breast Cancer Detection: A Randomized Clinical Trial

    Abstract Full Text
    free access is active quiz
    JAMA. 2016; 315(18):1956-1965. doi: 10.1001/jama.2016.5257

    This cluster random clinical trial tested the effects of reversing the order in which mammograms were read by a second radiologist on the rates of breast cancer detection among 46 screening centers in England.

  • JAMA May 10, 2016

    Figure 1: Proposed Mechanism of Action of Changing Case Order Intervention, Assuming the Hypothesized Vigilance Decrement

    Each screening represents examining a set of 4 mammograms, mediolateral oblique and craniocaudal views of both breasts for one woman.
  • JAMA April 26, 2016

    Figure: Adult Dense Breast Notification (DBN) Literacy Among 19 States

    The Flesch-Kinkaid reading level scale has a theoretical lower bound of −3.4 and no upper bound.
  • Diagnostic Concordance Among Pathologists Interpreting Breast Biopsy Specimens

    Abstract Full Text
    free access has multimedia
    JAMA. 2015; 313(11):1122-1132. doi: 10.1001/jama.2015.1405

    Elmore and coauthors quantify the magnitude of diagnostic disagreement among pathologists from 8 US clinical practices compared with a consensus panel reference diagnosis and evaluate associated patient and pathologist characteristics.

  • JAMA March 17, 2015

    Figure 3: Comparison of 115 Participating Pathologists’ Interpretations vs the Consensus-Derived Reference Diagnosis for 6900 Total Case Interpretationsa

    DCIS indicates ductal carcinoma in situ.aConcordance noted in 5194 of 6900 case interpretations or 75.3%.bReference diagnosis was obtained from consensus of 3 experienced breast pathologists.
  • JAMA February 3, 2015

    Figure: Recent Findings May Inform Breast Density Notification Laws

    Dense breasts have excess fibrous or glandular tissue. Pictured above are mammographic images of breast tissue with scattered fibrograndular density (Left) and extreme density (Right).
  • Breast, Cervical Cancer Screening for Millions of US Women

    Abstract Full Text
    JAMA. 2014; 312(13):1292-1292. doi: 10.1001/jama.2014.11463
  • Breast Cancer Screening Using Tomosynthesis in Combination With Digital Mammography

    Abstract Full Text
    free access has multimedia
    JAMA. 2014; 311(24):2499-2507. doi: 10.1001/jama.2014.6095

    Friedewald and coauthors conducted a retrospective analysis of screening performance metrics to determine if addition of tomosynthesis to digital mammography improved performance of US breast screening programs. Pisano and Yaffe comment in an Editorial.

  • JAMA October 2, 2013

    Figure 1: Anatomical Landmarks of the Axilla and Lymphatic Drainage of the Breast

    Sentinel nodes are identified within levels 1 and 2. Anatomical landmarks of the thoracodorsal bundle, long thoracic nerve, and axillary vein are used to delineate tissue removed during a level 1 and 2 complete axillary lymph node dissection.
  • JAMA July 24, 2013

    Figure: Supreme Court Rules Against Gene Patents

    The discovery of the BRCA1 gene and its role in hereditary breast and ovarian cancers in the early 1990s by Mary-Claire King, PhD, of the University of Washington, sparked a race to isolate and patent BRCA1 and a related gene, BRCA2. But a recent Supreme Court decision invalidated such patents.
  • Sorting Through the Arguments on Breast Screening

    Abstract Full Text
    JAMA. 2013; 309(24):2553-2554. doi: 10.1001/jama.2013.6822
  • JAMA June 12, 2013

    Figure: Cumulative Prevalence of Chronic Health Conditions for Representative Groups of Organ-Specific Outcomes According to Age

    Curves reflect cumulative prevalences based on proportion of participants diagnosed with a condition before and after participation in the St Jude Lifetime Cohort Study (SJLIFE) and undergoing follow-up until October 31, 2012. aFor cardiomyopathy, at risk defined as radiation therapy to the heart or exposure to anthracycline or anthroquinone; for heart valve disorder, as radiation to the heart; for pituitary dysfunction, as radiation (≥18 Gy) to the hypothalamus-pituitary; for pulmonary dysfunction, as thoracotomy, radiation to the lungs, or exposure to bisulfan, carmustine/lomustine, or bleomycin; for hearing loss, as radiation (≥30 Gy) to the ear or exposure to cisplatin or carboplatin; for breast cancer, as female sex and radiation (≥20 Gy) to the breast. bAs part of the core assessment battery, all participants were evaluated for dyslipidemia and gonadal failure.
  • From JAMA ’s Daily News Site

    Abstract Full Text
    JAMA. 2013; 309(18):1884-1884. doi: 10.1001/jama.2013.4959
  • JAMA October 24, 2012

    Figure: Breast Density and Cancer

    Having dense breasts is not associated with an increased risk of death among women with breast cancer, a recent study has found.
  • JAMA September 5, 2012

    Figure: Example of a Patient With Better Exclusion of the Heart and Lung When Prone

    Placing the posterior edge of the fields on a plane connecting the midline to the anterior extent of the latissimus dorsi muscle ensures comparable breast coverage.
  • JAMA September 5, 2012

    Figure: Effect of BRMs on Occurrence of Specific Types of Cancer in Patients With Rheumatoid Arthritis

    BRM indicates biologic response modifier; OR, odds ratio; TNF, tumor necrosis factor. Numbers of patients included in each comparison are reported in eTable 5. Diamonds represent pooled effect estimates with 95% CIs for all TNF inhibitors. aFor infliximab, 1 patient reported both squamous cell carcinoma and melanoma. bAdrenal, bladder, breast, cholangiocarcinoma, fibrosarcoma, gastrointestinal, hepatic, leiomyosarcoma, liposarcoma, lung, ovarian, pancreatic, prostate, renal, testicular, thyroid, tongue, and uterine. cMultiple myeloma and leukemia.
  • Whistle-blower Treatment

    Abstract Full Text
    JAMA. 2012; 307(10):1015-1015. doi: 10.1001/jama.2012.257
  • The Harms of Screening: New Attention to an Old Concern

    Abstract Full Text
    JAMA. 2012; 307(6):565-566. doi: 10.1001/jama.2012.100
  • JAMA October 21, 2009

    Figure 2: Age-Adjusted Incidence Rates of Breast and Prostate Cancer Over Time and by Prescreen and Postscreen Snapshot

    A, Age-adjusted incidence rate by stage of invasive female breast cancers for all ages, SEER 1973-2006. Mammography was introduced in 1983 and more widely used beginning in 1986. The incidence per 100 000 women of localized, regional, and metastatic breast cancer is shown over time (left), and for the period prior to the uptake of screening (1982) and 16 years after (1998) (middle). Local disease, as a fraction of all cancers reported, is shown on the right. B, Age-adjusted incidence rate of adenocarcinoma of the prostate for men older than 24 years, SEER, 1973-2006. Prostate cancer screening began in 1986 and was more widely used beginning in 1989-1990. Given the degree of missing data for prostate cancer TNM stage in SEER, we chose to show the change in Gleason grade, a significant predictor of outcome since the introduction of screening. The middle panel shows the incidence per 100 000 men of tumors with Gleason grades that were low- and intermediate-grade (2-7) vs high-grade (8-10) tumors, for the period prior to the uptake of screening (1988) and 16 years after (2004). The low- and intermediate-grade tumors as a fraction of all cancers is shown in the panel on the right.